Die Entdeckung bzw. Wiederentdeckung der blutzuckersenkenden Wirkung von Sulfonylharnstoffen im Jahre 1955 durch FRANKE und FUCHS hat die For- schung sowohl uber die Physiologie der Langerhansschen Inseln als auch uber den Kohlenhydratstoffwechsel sehr angeregt. Nachdem es wahrscheinlich wurde, dass Substanzen aus der Gruppe der Sulfonylharnstoffe die Sekretion von Insulin stimulieren, wurden verschiedene Methoden zur Bestimmung von Insulin im Blut entwickelt, die wegweisend fur empfindliche Methoden zur Bestimmung anderer Peptidhormone waren, und die elektronenmikroskopischen Beobachtungen der Vorgange bei der Sekretion von Insulin aus den B-Zellen wurden zum Modell fur die Vorstellungen uber die Funktion anderer Drusen. Es gibt viele Substanzen, die die Insulin-Sekretion aus den B-Zellen beeinflus- sen, die Zucker Glucose und Mannose, die Aminosauren Arginin und Leucin, ver- schiedene kurzkettige Fettsauren, verschiedene Metaboliten des intermediaren Stoffwechsels und Hormone, wie Glucagon, Corticotropin, Secretin, Gastrin, Pankreozym und verschiedene andere. In diesem Band sollten die therapeutisch interessanten Pharmaka abgehandelt werden, zu denen vor allem die Gruppen der Sulfonylharnstoffe bzw. Sulfonamide und der Biguanide gehoren. Auf die Geschichte der Verwendung von Biguaniden zur Behandlung von Diabetikern geht BECKMANN in seinem Artikel ausfuhrlich ein, so dass sich eine Darstellung hier erubrigt. Die blutzuckersenkenden Sulfonylharnstoffe wurden 1955 sozusagen durch eine klinische Zufallsbeobachtung mit Carbutamid wieder entdeckt und fur die Therapie zuganglich gemacht, nachdem LOUBATIERES sich mit der Wirkung ahnlicher Substanzen auf den Blutzucker und auf die Langerhans'schen Inseln bereits seit Anfang der 40er Jahre ausfuhrlich experimentell beschaftigt und bereits prinzipielle Aussagen uber den Wirkungsmechanismus gemacht hatte, die auch heute noch weitgehend akzeptiert werden.

Traditional Chinese medicine has been used for thousands of years by a large population. It is currently still serving many of the health needs of the Chinese people; and still enjoying their confi dence it is practised in China in parallel with modern Western medical treatment. In addition to scientific organisations dedi cated to modern Western medicine, e. g. the Chinese Academy of Medical Sciences and various medical schools, a series of parallel institutions have been established in China to promote traditional Chinese medicine, such as the Academy of Traditional Chinese Medicine and training institutions. Almost all hospitals in China have a department of traditional medicine. Furthermore, a large number of scientific journals are dedicated to traditional Chinese medicine, covering both experimental and clinical investigations. Medicinal materials constitute a key topic in the treatment of disease according to traditional Chinese medicine. The Chinese Pharmacopoeia (1985 edition) is therefore divided into two sepa rate volumes, Volume I containing traditional Chinese medicinal materials and preparations and Volume II containing pharmaceu tics of Western medicine. The oldest Chinese review of medicinal materials, Shennong Bencao Jing (100-200 A. D. ), covered 365 herbal drugs. The clas sic compilation in this field, Bencao Gangmu (Compendium of Materia Medica), was published in 1578 by Li Shi-zhen and recorded as many as 1898 crude drugs of plant, animal and min eral origin."

More than a year ago the three editors sat down at a table and worked out a set of six chapter headings which they believed might serve, in turn, for each of the three sections of this handbook. (The reader will note a similarity in order of presentation and in emphasis.) However, as our editorial plans progressed it became apparent that for each element and for the element group, there were one or two special topics appropiate for that section alone. Accordingly, in the section on uranium the common pattern holds for Chaps. 1 through 6 which include: an introduction (Chap. 1), a discussion of the physical and chemical properties (Chap. 2), experimental data on animals (Chap. 3), ex perimental data on man (Chap. 4), the rationale and development of air con centration limits to control industrial worker exposure (Chap. 5), and the prac tical problems of applying such limits in the uranium industry (Chap. 6). Chap. 7 entitled "Uranium Mining Hazards" is the subject category which is special for uranium; the chapter brings up to date the account of an important occupational hazard which was first noted by GEORGIUS AGRICOLA (1490-1555)."

It is quite amazing that the oldest group of medically useful antibiotics, the p-Iactams, are still providing basic microbiologists, biochemists, and clinicians with surprises over 50 years after Fleming's discovery of penicillin production by Penicillium. By the end of the 1950s, the future of the penicillins seemed doubtful as resistant strains of Staphylococcus aureus began to increase in hospital populations. However, the development of semisynthetic penicillins provided new structures with resistance to penicillinase and with broad-spectrum activity. In the 1960s, the discovery of cephalosporin C production by Cephalosporium and its conversion to valuable broad-spectrum antibiotics by semisynthetic means excited the world of chemotherapy. In the early 1970s, the 40-year-old notion that p-lactams were produced only by fungi was destroyed by the discovery of cephamycin production by Streptomyces. Again this basic discovery was exploited by the development of the semisynthetic cefoxitin, which has even broader activity than earlier p-lactams. Later in the 1970 s came the discoveries of nocardicins from Nocardia, clavulanic acid from Streptomyces, and the carbapenems from Streptomyces. Now in the 1980s we learn that p-lactams are produced even by unicellular bacteria and that semisynthetic derivatives of these monobactams may find their way into medicine. Indeed, the future of the prolific p-lactam family seems brighter with each passing decade.

The cells of the immune system generate a large variety of binding sites which differ in their binding specificities and can therefore react specifically with a large variety of ligands. These binding sites are part of receptor molecules, enabling the system to react to the universe of antigens. The classical antigen receptor is the antibody molecule, and accord ingly the first session of this colloquium deals with a classical sub ject, namely antibody structure. Dramatic recent advances in this field make it possible to interrelate primary and three-dimensional struc ture both to each other and to function, i.e. the binding of antigen and possible reactions occurring in the antibody molecule upon antigen binding. The latter point is of particular interest since it may be relevant not only for effector functions of antibodies such as the binding of complement, but also for the triggering of a lymphocyte through its antibody receptor for antigen."

When I was asked some years ago by the editors of the Handbook of Experimental Pharmacology to edit a new volume on Antianginal Drugs, I agreed on the condition that, in accordance with my scientific background, primary emphasis be given to clinical pharmacology and therapeutics. It soon turned out that, due to rapid developments in this field, nothing of the previous volume on Antianginal Drugs by Charlier (Vol. 31, 1971) could be retained apart from its basic idea of devoting considerable space to methodology. Since editors must operate within certain limits, I had to abstain from dealing with acute myocardial infarction in detail despite the well-known overlap between unstable angina, the preinfarction syndrome, and acute myocardial infarction. It was only possible for acute myocardial infarction and the concept of reduction of infarct size to be briefly discussed within the chapter on pathophysiology of acute coronary insufficiency. The chapter on invasive methods provided an opportunity to touch on new approaches to early intervention in acute myocardial infarction. Here, intracoronary streptokinase therapy and PTCA are considered, again with attention to the overlap between mechanical and pharmacological interventions.

The development of a new antiarrhythmic drug involves many people with disparate skills. The organic chemist who makes it is guided not only by the structure-action relations of previous compounds, but by anticipation of a requirement for a particular type of action. In fact several of the best-known antiarrhythmics, including lidocaine, mexiletine, amiodarone and verapamil, were originally synthesized for other purposes. Physicians have to determine whether the new drug works, and pharma cologists how it works. For some years I have believed that there was room for a work which could be understood by all these groups and which could enlighten each about the point of view of the others. Thus when I was invited by Springer-Verlag to prepare a volume in their series Handbook of Experimental Pharmacology, I already had a firm conception of what its form should be. In any multi-author work there are two objectives which cannot always readily be reconciled. The first is to select topics which would relate to each other in a coherent manner. to give a logical and orderly shape to the volume as a whole. The second is to offer authors the greatest possible freedom to express themselves as they wish. When the general design was complete, prospective contributors were invited to write specific chapters, being provided with a complete list of their coauthors and chosen topics, so that they could avoid overlap."

" . . . the motto for the therapeutics of the future will have to be de sedibus et causis pharmacorum. " P. EHRLICH, 1909 Exciting events in the basic disciplines of virology, immunology, and pharmacology continue to advance the understanding of the pathogenesis and control of virus diseases. At the same time, the rational development of antiviral agents is attracting, to an increasing extent, the interest of workers in other disciplines. Improvements in technology facilitate the definition of potential target sites for antiviral intervention and unmask new viral and host genes. The outcome is a further steady development of new antiviral agents which approach the "magic bullets" first proposed by PAUL EHRLICH. Remarkable advances in protein synthetic methods that yield polypeptides which inhibit active sites of viral proteins have aided substantially in the basic and clinical study of these antiviral agents. In addition, the extremely rapid progression in recombinant DNA techniques, leading to the synthesis of large quantities of gene products, is also increasing our opportunities at a dashing pace. New information and developing technology facilitate research on the mechanism of action, toxicity, pharmacokinetics, and pharmacodynamics of new agents. The list of clinically effective antiviral agents is expanding and the number of potentially useful compounds is growing rapidly. This book is a combined theoretical text and practical manual which, it is hoped, will be of use to all who have an interest in virus diseases, particularly scientists, physicians and graduate students.

Epileptic disorders need treatment for many years or even for life, and this makes a thorough understanding of the pharmacokinetics and possible hazards and side effects of the drugs used in treatment mandatory. During recent decades our knowledge in this field has considerably increased, not least as a result of the development of specific and sensitive methods for the determination of anti epileptic agents in biological material. The clinical pharmacology of this group of drugs has been studied extensively and can today be regarded as well established. This does not necessarily mean that drug treatment of epilepsy is without problems. For example, it has recently been shown that one of the newer anti epileptic drugs, greeted with great enthusiasm by clinicians, may in rare instances induce serious damage to the liver and the pancreas, and seems even to have a certain teratogenic potential. Clinical problems should be understood as a challenge to the experimental pharmacologist, who should try to find explanations for the clinical hazards, and, if possible, show new ways in which better drugs might be developed. In recent years interest has focused on the importance of the inhibitory transmitter 'l'-aminobutyric acid (GABA) in the pathophysiology of epilepsy, and there have been a series of attempts to find useful antiepileptic drugs among substances interfering with GABA metabolism in the CNS."

Since the exhaustive Handbook of Physiology (Alimentary Canal, Section 6, Motility) edited by CHARLES F. CODE in 1968, no complete survey of the morphological basis and the physiological control of intestinal motility has been published, in spite of the enormous amount of new data in the literature on this topic. The new techniques and methodologies, the use of electron microscopy, radioimmunoassay and binding techniques, as weIl as ever more sophisticated electrophysiological procedures have made possible areal flood of discoveries in this field. Moreover, the possibility ofnew studies ofthe endocrine cells in biopsies of human intestinal mucosa even during routine endoscopies, has opened new horizons for gastroenterologists and generated a number of important contribu tions to our knowledge of the morphology and physiopathology of the gut. As usual, new discoveries have also revealed both ignorance and many new problems. For tbis reason, although many of the data reported in this volume can be considered as firmly established, others still require confirmation, and the results of new research in this field are awaited with extreme interest. Since advances are occurring so rapidly, even experts in the specific topics need frequent comprehensive reviews. To avoid an excessively large volume, considera tions ofthe pancreas, liver, and biliary system were not included in this Handbook, which, nevertheless, has attempted to off er the reader the essence of more than 1,500 papers."

Combining two separate textbooks entitled Essentials of Human Physiology for Pharmacy and Essentials of Pathophysiology for Pharmacy into one cohesive volume, this new book seamlessly integrates material related to normal human physiology and pathophysiology into each chapter. Chapters include: Study objectives at the beginning of each chapter; Summary tables, flow charts, diagrams, and key definitions; Real life case studies to emphasize clinical application and stimulate student critical thinking; An emphasis on the rationale for drug therapy; Simple, straightforward language. Written by authors with extensive teaching experience in the areas, Essentials of Human Physiology and Pathophysiology for Pharmacy and Allied Health is a concise learning instrument that will guide students in pharmacy and allied health programs.

Local anesthetics are among the most widely used drugs. Their development over the past century ranges from a documented influence on Freud's Interpretation of Dreams 1 to the synthesis of the ubiquitously popular lidocaine, as described in Chapter 1. For surgical procedures the use of regional, epidural and intrathecal local anesthesia has increased continuously during the past decade. Local anesthetics are also applied by physicians to ameliorate unpleasant sensations and reactions to other procedures, such as tracheal intubation. The presence or the threat of cardiac arrhythmias is often countered by chronic administration oflocal anesthetic-like agents, such as lidocaine or procainamide. Relief of acute pain, accompanying dental manipulations, for example, and of chronic pain are also accomplished with traditional local anesthetics. And over-the-counter formula tions of topical local anesthetics provide practitioners of solar indiscretion welcome relief from their otherwise unaccommodating sunburn. In all these applications the final effect of the local anesthetic is an inhibition of electrical activity, accomplished as a reduction or total blockade of action potentials. The primary site of action is the sodium channel, a transmembrane protein which is essential for the influx of sodium ions that subserves impulse generation and propagation in nerves, skeletal muscle, and heart. The detailed mechanisms oflocal anesthetic action are still being investigated and Chapter 2 of this volume provides a current overview of that subject."

The history of antibiotics may weIl have begun with the ancient Sudanese-Nubian civilization (see Chapter 1, "Historical Introduction"), but this volume reflects a more contemporary appraisal of the antibiotic era. We have compiled a comprehensive review of the tetracyclines which includes all the major sub divisions of these chemically important and clinically useful antibiotics. There can be little doubt about the contribution of antibiotics to both the increase in human life span and the alleviation of much human suffering. The tetracyclines are still playing an important role in these areas and will continue to do so in the foreseeable future. We hope this volume will be an important contribution to a better under standing of the chemistry, biochemistry, and medical aspects of tetracycline antibiotics. We are indebted to the individual authors who have given so much of their time and effort in the preparation of the chapters. Pearl River, NY J OSEPH J. HLA VKA Ocean Gate, NJ JAMES H. BOOTHE Contents CHAPTER 1 Historical Introduction. J. H. BOOTHE and J. J. HLAVKA References. 3 CHAPTER 2 Fermentation and Mutational Development of the Tetracyclines J. J. GOODMAN A. Introduction 5 B. The Producing Microorganisms . 6 I. Morphology and Ultrastructure 6 11. Mutation and Strain Selection 8 111. Cosynthesis. 13 The Fermentation Process 14 C. I. Inoculum 14 11. Contamination 16 Complex Media. 18 111. IV. Synthetic Media. 27 V. Stimulators and Inhibitors 30 Directed Fermentations 32 VI."

The purpose of the present volume, the first of two on the pharmacology, biochemistry, and physiology of cyclic nucleotides, is to provide a comprehensive and up-to-date anthology on the nature and role of these important chemical regulators. Each of the chapters is the work of internationally known researchers who present a lucid and detailed review of their subject and not merely a single laboratory's viewpoint. The chapters emphasize critical assessments of the field rather than mere listings of experimental findings. By so doing, the contributors present the role of cyclic nucleotides in relationship to other intracellular regulators. Each chapter begins with a detailed summary to allow the reader to obtain a rapid overview of subsequent material. In addition, there are extensive bibliographies and a detailed subject index. Wherever pertinent, the chapters contain sections on drug mechanisms, physiological relevance, and disease processes. The Volume is divided into two sections, each beginning with an overview written by Professors T. W. RALL and P. GREENGARD, respectively. The first section focuses on the detailed pharmacology and chemistry of cyclic nucleotides, including their formation, degradation, measurement, and interaction with various modulatory agents, such as receptors and calcium. The second section is concerned with the biochemistry of protein phosphorylation, a process which appears to be one of the most important mechanisms for the intracellular expression of cyclic nucleotide action in eukaryotic cells.

The description of the pharmacology of psychotomimetics, cannabis, and alcohol in this third volume concludes the discussion on psychotropic agents. As psychomotor stimulants these groups of psychotropic agents are of little or no therapeutic relevance, but since they are used in a nonmedical manner, or are even considered by some groups of the population as social commodities, their behavioral effects and psychopharmacological properties are not the concern of the pharmacol ogist alone. The same is true of psychotomimetics, as well as cannabis and its components. Psychotomimetics have a social history going back many hundreds of years and are among the most potent psychotropic agents known to man. The closing description of psychopharmacology also deals with the psychotropic effects of a number of drugs not primarily considered to be psychotropic. Their psychotropic effects are either an inherent constituent of their therapeutic profile, as is the case with opiates, hypnotics, and caffeine, or they may occur indirectly as side effects or accompanying effects during therapy. This applies to p-adrenoreceptor antagonists and anticholinergics. The editors are also aware that a description of psychotropic agents would not have been complete without discussing the medical, ethical, and legal aspects of the development, clinical testing, and use of such drugs."

Bereits 3 Jahre nach dem ersten Adriamycin-symposium und 2 Jahre nach der Veroffentlichung der Referate jener Tagung erschien es angezeigt, Wissenschaftler aus aller Welt erneut zusammenzurufen, um tiber die inzwischen gewonnenen Erfahrungen mit Adriamycin zu berichten. Nachdem in einer ersten Phase die Wirkung dieses Chemotherapeutikums ftir die systemischen Krebserlaankungen erkannt und erforscht war, konnte in vielen kontrollierten Studien an bedeutenden, mit der Krebs- forschung befassten 1nstituten in aller Welt nachgewiesen werden, dass Adriamycin heute auch in der Bekampfung solider Tmnoren zu einem wich- tigen, in der Krebs-Therapie wirksamen Pharmakon gezahlt werden muss. Die Vortrage dieses Symposiums unterstreichen die wichtige Rolle die- ser ftir die moderne cytostatische Therapie bedeutsamen Substanz. Der Sinn dieser Tagung ist, auch ftir die Zukunft neue Anregungen ftir For- schung und internationa.le Zusammenarbei t beim Kampf gegen den Krebs zum Wohle des Patienten zu gewinnen. D. Schmahl Die Veroffentlichung der Referate des zweiten Adriamycin-Symposiums sollte moglichst rasch erfolgen und in kurzer Zeit dem interessier- ten und onkologisch tatigen Arzt zur Verftigung stehen. Deshalb haben wir uns entschlossen, auf ein Sachregister und ein ausftihrliches Li- teraturverzeichnis in diesem Buche zu verzichten, was dankenswerter- weise unter diesen Voraussetzungen vom Springer Verlag akzeptiert wurde. Allen Vortragenden und allen Beteiligten bei der Durchftihrung des Symposiums mochten wir an dieser Stelle unseren besonderen Dank sagen.

This second volume continues the description of the psychotropic agents and discusses anxiolytics, gerontopsychopharmacological agents, and psychomotor stimulants. Of these groups of substances, most of this volume has been devoted to anxiolytics as the authors have endeavored to convey as complete a picture as possible. The editors are of the opinion that particular attention should be given to anxiolytics with regard to their range of administration as this is the most frequently prescribed group of psychotropic drugs. In contrast to neuroleptics and thymoleptics, anxiolytics are a class of psychotropic drugs whose therapeutic effect can be recognized in animal experiments to some extent. This, together with the analysis of the biochemical mechanisms of their actions, permits a better understanding of material processes in the brain accompanying the emotions: anxiety and tension. For the first time in the history of the Handbook the editors have devoted a whole chapter to gerontopsychopharmacological agents. In doing so they are also aware of the risk they are taking, at least from a pharmacological point of view, as gerontopsychopharmacological agents are an insufficiently defined and extremely heterogeneous group of substances. The only denominator the various subgroups of these agents have in common is that they are given in cases of dysfunctions, disorders, and diseases of the brain occurring mainly in the elderly.

Catecholamines 1922 -1971 H. BLASCHKO Adrenaline and related substances were discussed in the 1924 edition of Hefl'ter's Handbook by PAUL TRENDELENBURG. On 164 pages he described what was then known not only of adrenaline and its closest relatives but also of the sympathomimetic compounds such as tyramine and ephedrine. When the present Editors of the Handbook entrusted us with the task of editing the present Volume it was decided to restrict it to adrenaline and the other naturally occurring catecholamines. The sympathomimetic amines in general will be discussed only in their relation to the catecholamines. Since TRENDELENBURG completed his review this field has undergone an enormous expansion. There has been a wealth of new findings, and a succession of new ideas. The new theories that have been built into contemporary thought will be fully discussed in the succeeding contributions. But many of the hypotheses that have been put forward since 1924 have long been discarded and yet, they have often led to important observations that we still consider as valid.

In 1970 I gave up the chairmanship of the Department of Pharmacology at Stanford University Schoel of Medicine to devote full time to basic and clinical research on problems of drug addiction. In 1971 I developed the method of radioligand binding that led to the important characterization of opioid receptors in several laboratories. The extraordinary specificity of these receptors for morphine and related opiates suggested the likelihood that there were naturally occurring morphine-like molecules in the brain and other tissues. The systematic search for these molecules culminated in 1979 in the discovery, by my group, ofthe dynorphin peptides-one of the three families of opioid peptides, the first of which (the enkephalin family) had been discovered in Aberdeen, Scotland, in 1975. I also became involved in clinical research on the pharmacologic treatment of heroin addicts, for which I established the first large methadone mainte nance treatment program in California. My basic and clinical research experience convinced me that an institution encompassing laboratory research, studies on normal human volunteers, and treatment research, under a single roof, could expedite progress in understanding the drug addictions. That concept was transformed into reality by the founding, in 1974, of the Addiction Research Foundation of Palo Alto, California. The funds for construction of a laboratory were provided by a generous grant from the Drug Abuse Council (a consortium of several foundations), the president of which was Thomas L. Bryant."

This book deals with principles in g

MTDSC provides a step-change increase in the power of calorimetry to characterize virtually all polymer systems including curing systems, blends and semicrystalline polymers. It enables hidden transitions to be revealed, miscibility to be accurately assessed, and phases and interfaces in complex blends to be quantified. It also enables crystallinity in complex systems to be measured and provides new insights into melting behaviour. All of this is achieved by a simple modification of conventional DSC.

In 1992 a new calorimetric technique was introduced that superimposed a small modulation on top of the conventional linear temperature program typically used in differential scanning calorimetry. This was combined with a method of data analysis that enabled the sample s response to the linear component of the temperature program to be separated from its response to the periodic component. In this way, for the first time, a signal equivalent to that of conventional DSC was obtained simultaneously with a measure of the sample s heat capacity from the modulation. The new information this provided sparked a revolution in scanning calorimetry by enabling new insights to be gained into almost all aspects of polymer characteristics.

This book provides both a basic and advanced treatment of the theory of the technique followed by a detailed exposition of its application to reacting systems, blends and semicrystalline polymers by the leaders in all of these fields. It is an essential text for anybody interested in calorimetry or polymer characterization, especially if they have found that conventional DSC cannot help them with their problems.

Cell Culture Methods for in vitro Toxicology introduces the reader to a range of techniques involved in the use of in vitro cell culture in toxicological studies. It deals with major cell types studied in the field of toxicology and will be useful for anyone wishing to start work with animal cell cultures or to refresh their knowledge relating to in vitro cell models. Fundamental chapters deal with the general biology of cytotoxicity and cell immortalisation these are key issues for in vitro systems addressing the 3Rs' principle. Up-to-date overviews deal with the use of cells from liver, brain and intestine. In addition, biochemical analysis of cell responses, biotransformation pathways in cells and recombinant approaches to the early detection of cell stress are also covered in detail. Prominent features of in vitro technologies also include regulation, biosafety and standardisation. Dedicated chapters deal with these issues in a practical way in order to lead the reader to the right source of information. This book provides an up-to-date, informative and practical review of cell culture methods for in vitro toxicology. It will be of equal benefit to students and experienced toxicologists with little experience of in vitro cell culture.

The use of various pharmaceutical carriers to enhance the in vivo efficiency of many drugs and drug administration protocols has been well established during the last decade in both pharmaceutical research and clinical setting. Surface modification of pharmaceutical nanocarriers, such as liposome, micelles, na- capsules, polymeric nanoparticles, solid lipid particles, and niosomes, is normally used to control their biological properties in a desirable fashion and to simulta- ously make them perform various therapeutically or diagnostically important functions. The most important results of such modification include an increased stability and half-life of drug carriers in the circulation, required biodistribution, passive or active targeting into the required pathological zone, responsiveness to local physiological stimuli, and ability to serve as contrast agents for various imaging modalities (gamma-scintigraphy, magnetic resonance imaging, computed tomography, ultra-sonography). Frequent surface modifiers (used separately or simultaneously) include soluble synthetic polymers (to achieve carrier longevity); specific ligands, such as antibodies, peptides, folate, transferrin, and sugar moieties (to achieve targeting effect); pH- or temperature-sensitive lipids or polymers (to impart stimuli sensitivity); chelating compounds, such as EDTA, DTPA, and deferoxamine (to add a heavy metal-based diagnostic/contrast moiety onto a drug carrier). Certainly, new or modified pharmaceutical carriers (nanocarriers) as well as their use for the delivery of various drugs and genes are still described in many publications.

An extraordinary compendium of information on herbal medicine, Medicinal Plants of the World, Volume 3 comprehensively documents the medicinal value of 16 major plant species widely used around the world in medical formulations. The book's exhaustive summary of available scientific data for the plants provides detailed information on how each plant is used in different countries, describing both traditional therapeutic applications and what is known from its use in clinical trials. A comprehensive bibliography of over 3000 references cites the literature available from a wide range of disciplines. This book offers an unprecedented collection of vital scientific information for pharmacologists, herbal medicine practitioners, drug developers, medicinal chemists, phytochemists, toxicologists, and researchers who want to explore the use of plant materials for medicinal and related purposes.